About Pasithea Therapeutics Corp. - Common Stock (KTTA)
Pasithea Therapeutics Corp is a biotechnology company focused on the development of innovative therapies for the treatment of psychiatric and neurological disorders. The company is committed to leveraging advanced scientific research and cutting-edge technologies to create new treatment options that address unmet medical needs in these challenging areas. Pasithea aims to improve the quality of life for patients suffering from conditions such as depression and anxiety by exploring novel approaches in drug discovery and development. Through its work, Pasithea seeks to make a meaningful impact on mental health care and enhance overall well-being in affected individuals. Read More
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Pasithea Therapeutics reports encouraging early Phase 1 data for PAS-004, showing no adverse events or toxicities. The trial highlights safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
